$11,459.50 consulting Payment -- Bristol-Myers Squibb to Dr. Gregory Evans
Hepatologist Gregory Evans Receives $11,459.50 Consulting Fee from Bristol-Myers Squibb
This page provides a detailed analysis of a $11,459.50 consulting payment from Bristol-Myers Squibb to Dr. Gregory Evans. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $11,459.50 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Bristol-Myers Squibb |
| Physician | Dr. Gregory Evans |
| NPI Number | 1735782150 |
| Physician Specialty | Hepatology |
| Location | Allentown, PA |
| Date of Payment | 2025-09-21 |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Bristol-Myers Squibb made a $11.5K consulting payment to Gregory Evans, a Hepatology specialist in Allentown, PA. Gregory Evans received a $11,459.50 consulting fee from Bristol-Myers Squibb on September 21, 2025. The payment was for consulting services related to Hepatology. This payment represents a significant financial engagement between the physician and the pharmaceutical company.
Patient Guidance: What This Payment Means for You
If you are a patient of Dr. Evans, this information details a professional consulting engagement he had with Bristol-Myers Squibb, a pharmaceutical company, which may be relevant to understanding potential influences on medical advice. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Consulting fees for specialists in Hepatology can vary widely, but this amount is on the higher end for a single engagement, suggesting a potentially significant advisory role.
Regulatory Context: Sunshine Act Requirements
Physicians receiving payments from pharmaceutical companies are required to have these transactions reported under the Sunshine Act to ensure transparency in the healthcare industry.
Related Topics
This payment is related to the following healthcare transparency topics:
- hepatology
- consulting-fee
- bristol-myers-squibb
- physician-payment
- cms-open-payments
- pharmaceutical-industry
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $11.5K payment for?
This was a consulting payment of $11.5K from Bristol-Myers Squibb to Gregory Evans, categorized as "Consulting Fee". The payment was reported under the Sunshine Act (CMS Open Payments).
Does Gregory Evans accept pharmaceutical money?
Yes, Gregory Evans received this $11.5K payment from Bristol-Myers Squibb. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Gregory Evans's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $11.5K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Hepatology?
To compare this payment against Hepatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hepatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Gregory Evans's relationship with Bristol-Myers Squibb?
The payment amount is substantial for a single consulting engagement. This $11.5K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Hepatology?
The payment date is in the future, suggesting a pre-arranged agreement.
What should patients do after learning about this payment?
If you are a patient of Dr. Evans, this information details a professional consulting engagement he had with Bristol-Myers Squibb, a pharmaceutical company, which may be relevant to understanding potential influences on medical advice.
What else should I know about this consulting payment?
The specific nature of the consulting is listed as 'Consulting Fee'.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.